How Medicines Law & Policy
is Aiding the Covid-19 Response
is Aiding the Covid-19 Response
European Union Review of Pharmaceutical Incentives:
Suggestions for Change
A new briefing paper series from Medicines Law & Policy
Suggestions for Change
A new briefing paper series from Medicines Law & Policy
EU Review of Pharmaceutical
Incentives: Suggestions for Change
Incentives: Suggestions for Change
Medicines Law & Policy creates tools countries and others looking to increase access to medicines can use to overcome patent barriers when needed.
Medicines Law & Policy maintains a database
documenting use of TRIPS Flexibilities
to increase access to medicines worldwide.
documenting use of TRIPS Flexibilities
to increase access to medicines worldwide.
Medicines Law & Policy releases analysis,
policy recommendations and tools to aid practitioners
working on universal access to medicines.
policy recommendations and tools to aid practitioners
working on universal access to medicines.
Latest insight from Medicines Law & Policy
The European Commission’s proposal for an EU wide compulsory licensing mechanism
In 2006 the European Generics Association was seeking clarification from the European Commission on whether generic versions of oseltamivir (Tamiflu) could be supplied to...
Updated TRIPS Flexibilities Database
In January 2023, a number of cystic-fibrosis patient organisations asked the governments of Brazil, India, South Africa and Ukraine to invoke compulsory licensing and...
New WHO-UNITAID briefing paper: Improving Access to Covid-19 Treatments
A new briefing paper based on Medicines Law & Policy research outlines the legal instruments available for countries seeking to access key therapeutics to...
Protecting Public Health through Technology Transfer: The Unfulfilled Promise of the TRIPS Agreement
This article was previously published by the Health and Human Rights Journal.
The scrambling for access to COVID-19 vaccines by developing countries has reignited the...
How not to solve a crisis: The European Commission’s Plan for Transferable Data Exclusivity...
Drug-resistant infections, sometimes called “superbugs,” killed an estimated 1.27 million people in 2019, a number set to rise to 50 million by 2050. It is...
Right to breathe takes precedence over company profits: Families of cystic fibrosis patients seek...
“Not even the doctors believed it would be so miraculous,” says 22-year old Rafaella Pereira. In two days, a new cystic fibrosis medicine took...
This work is licensed under